These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24184236)

  • 1. With age comes wisdom: is this true for platelets?
    Bonello L; Frère C; Paganelli F; Laine M
    J Am Coll Cardiol; 2014 Feb; 63(6):518-9. PubMed ID: 24184236
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos K; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e29. PubMed ID: 23591428
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Grove EL; Kristensen SD
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e28. PubMed ID: 23591427
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction.
    Perl L; Lerman-Shivek H; Rechavia E; Vaduganathan M; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Codner P; Bental T; Battler A; Kornowski R; Lev EI
    J Am Coll Cardiol; 2014 Feb; 63(6):513-7. PubMed ID: 24148715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differentiated antiplatelet therapy for acute coronary syndromes].
    Schäfer A; Arntz HR; Boudriot E; Garlichs C; Hoffmann S; Ince H; Klingenheben T; Weil J; Zugck C; Helms TM; Silber S
    Dtsch Med Wochenschr; 2014 Jan; 139(4):152-8. PubMed ID: 24430955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor or prasugrel for pre-hospital protocols in STEMI?
    Fournier N; Toesca R; Bessereau J; Champenois A; Mazille A; Luigi S; Yvorra S; Paganelli F; Brun PM; Michelet P; Meyran D; Auffray JP; Bonello L
    Int J Cardiol; 2013 Oct; 168(4):4566-7. PubMed ID: 23871340
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.
    Cuisset T; Cayla G; Quilici J; Pankert M; Deharo P; Bonnet G; Grosdidier C; Beguin S; Morange P; Bonnet JL; Alessi MC
    Int J Cardiol; 2013 Oct; 168(3):2988-9. PubMed ID: 23642612
    [No Abstract]   [Full Text] [Related]  

  • 11. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
    Brener SJ; Oldroyd KG; Maehara A; El-Omar M; Witzenbichler B; Xu K; Mehran R; Gibson CM; Stone GW
    Am J Cardiol; 2014 May; 113(9):1457-60. PubMed ID: 24630789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel.
    Deharo P; Pankert M; Bonnet G; Quilici J; Bassez C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2014 Oct; 176(3):1200-2. PubMed ID: 25156857
    [No Abstract]   [Full Text] [Related]  

  • 14. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
    Koziński M; Grześk G; Kubica J
    Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet therapy beyond 2012: role of personalized medicine.
    Tantry US; Budaj A; Gurbel PA
    Pol Arch Med Wewn; 2012; 122(6):298-305. PubMed ID: 22751292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 19. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes.
    Bonello L; Pansieri M; Mancini J; Bonello R; Maillard L; Barnay P; Rossi P; Ait-Mokhtar O; Jouve B; Collet F; Peyre JP; Wittenberg O; de Labriolle A; Camilleri E; Cheneau E; Cabassome E; Dignat-George F; Camoin-Jau L; Paganelli F
    J Am Coll Cardiol; 2011 Jul; 58(5):467-73. PubMed ID: 21777742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The illusion of "optimal" platelet inhibition.
    Steinhubl SR
    JACC Cardiovasc Interv; 2012 Mar; 5(3):278-80. PubMed ID: 22440492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.